Semaglutide and tirzepatide are remarkable medications. But they're not the end of the story. The weight-loss drug pipeline is more crowded and more promising than it has ever been, with next-generation treatments that could produce even greater weight loss, fewer side effects, and — critically — more affordable options.
If you're interested in where obesity pharmacotherapy is headed, or you're waiting for the "right" medication to come along, this is your roadmap.
What's available right now (as of April 2026)
Before looking ahead, here's the current landscape:
Semaglutide (Novo Nordisk): Ozempic, Wegovy (pill and injection), Wegovy HD (7.2mg). Generic semaglutide expected later in 2026 following patent expiry.
Tirzepatide (Eli Lilly): Mounjaro, Zepbound. Patent-protected through the early 2030s.
These two molecules cover the vast majority of GLP-1 prescriptions globally. But the pipeline behind them is deep.
Orforglipron — the needle-free future (Eli Lilly)
What it is: A small-molecule, non-peptide, once-daily oral GLP-1 receptor agonist. Unlike oral semaglutide (which is a peptide that needs careful absorption conditions), orforglipron is a small molecule that can be taken without fasting or water-timing restrictions.
Why it matters: This is potentially the most significant practical advancement in GLP-1 delivery. No injection. No 30-minute fasting window. Just a daily pill you take whenever it's convenient. That ease of use could dramatically expand the number of people willing to start and stay on GLP-1 therapy.
The data: The ACHIEVE-3 head-to-head trial showed orforglipron outperformed oral semaglutide on both blood sugar reduction (HbA1c ~2.2% vs ~1.4%) and weight loss (~9.2% vs ~5.3%) in adults with type 2 diabetes. For the weight-loss indication, the ATTAIN trials showed competitive results, with the ATTAIN-MAINTAIN study demonstrating that patients who switched from semaglutide to orforglipron maintained their weight loss — an important signal for long-term viability.
Timeline: Under FDA review now. Expected approval in 2026 through the FDA's National Priority Voucher programme. Eli Lilly is building a $6.5 billion manufacturing facility in Texas to support production.
What to watch for: Orforglipron's convenience advantage over oral semaglutide (no fasting requirement) could make it the preferred oral GLP-1. The head-to-head superiority data adds clinical credibility beyond convenience.
Retatrutide — the triple agonist (Eli Lilly)
What it is: A triple GIP/GLP-1/glucagon receptor agonist. While tirzepatide targets two hormones (GIP and GLP-1), retatrutide adds a third — glucagon — which increases energy expenditure and fat breakdown.
Why it matters: The weight-loss numbers are extraordinary. In phase 3 trials, retatrutide produced up to 28.7% mean weight loss — the highest ever recorded for a pharmacological obesity treatment. That's approaching the territory of bariatric surgery results.
The data: The TRIUMPH-4 trial in adults with type 2 diabetes showed up to 2.0% HbA1c reduction and 16.8% weight loss at 40 weeks. For obesity specifically, the phase 2 data showed up to 24.2% weight loss at 48 weeks, with the TRIUMPH programme's obesity-focused results expected to be the basis for regulatory submission.
Retatrutide also showed a 75.8% reduction in knee osteoarthritis pain (WOMAC scale) in obese adults — hinting at the "whole-body medicine" potential of next-generation GLP-1 drugs.
Timeline: Regulatory submission expected in 2026. If approved, this could become the most powerful single-drug obesity treatment available.
What to watch for: The glucagon component adds metabolic benefits but may have different tolerability characteristics. Longer-term safety data will be critical.
CagriSema — the combination approach (Novo Nordisk)
What it is: A once-weekly injection combining semaglutide (GLP-1 agonist) with cagrilintide (amylin analogue). Amylin is a hormone co-secreted with insulin that promotes satiety, slows gastric emptying, and reduces glucagon secretion.
Why it matters: By combining two complementary mechanisms, CagriSema aims to produce greater weight loss than semaglutide alone — without switching to a completely different molecular platform. For the millions of people already comfortable with semaglutide, this is an evolution rather than a revolution.
The data: Phase 3 results showed CagriSema produced approximately 22-24% mean weight loss in adults with obesity. However, in a head-to-head comparison with tirzepatide (the REDEFINE-2 trial), the results were mixed — CagriSema did not clearly separate from tirzepatide on the primary weight-loss endpoint, leading to some market uncertainty.
Timeline: Submitted for FDA approval in 2025. Regulatory decision expected in 2026.
What to watch for: If CagriSema doesn't clearly outperform tirzepatide, its commercial positioning becomes challenging. However, for patients already doing well on semaglutide who want more, it could be a natural step-up.
Aleniglipron — another oral option (Structure Therapeutics)
What it is: An investigational oral GLP-1 receptor agonist for obesity and overweight.
Why it matters: More oral GLP-1 options mean more competition and potentially lower prices for patients. The oral GLP-1 market is expected to capture approximately 24% of the global weight-loss drug market by 2030.
The data: Phase 2 results (ACCESS programme, announced March 2026) showed aleniglipron achieved up to 16.3% placebo-adjusted weight loss at 44 weeks with continued reductions through 56 weeks and no evidence of plateau. Tolerability was consistent with the GLP-1 class, with low rates of discontinuation due to side effects.
Timeline: Expected to advance into phase 3 in the second half of 2026. If trials succeed, approval could come in 2028-2029.
Survodutide — another dual agonist (Boehringer Ingelheim/Zealand Pharma)
What it is: A dual GLP-1/glucagon receptor agonist — different from tirzepatide's GIP/GLP-1 approach.
Why it matters: The glucagon component, like retatrutide, adds energy expenditure benefits. This drug is also being developed specifically for MASH (fatty liver disease), a massive unmet medical need.
The data: Phase 2 results showed significant weight loss and liver-specific benefits. Phase 3 trials are ongoing.
Timeline: Phase 3 completion expected in 2026-2027, with potential approval in 2028.
What does this mean for you right now?
If you're currently taking semaglutide or tirzepatide and getting good results — keep going. These medications work. The pipeline drugs are exciting, but they're not a reason to wait or to stop effective treatment.
If you're considering starting GLP-1 therapy and cost is a barrier, 2026 and 2027 bring multiple developments that could help: generic semaglutide, oral options that may be priced competitively, and increasing insurance coverage including Medicare expansion.
If you tried semaglutide or tirzepatide and the side effects were intolerable, the pipeline offers hope. Different molecular approaches may have different tolerability profiles. Orforglipron's small-molecule design and retatrutide's triple-agonist mechanism could work differently in your body.
The most important thing is that the pipeline is deep and competitive. Two years from now, we'll have more effective medications, more delivery options, and lower prices than at any point in the history of obesity pharmacotherapy. The field is moving fast — and it's moving in the right direction.
Key Studies & References
-
Wharton et al. (2025) — The STEP UP trial (semaglutide 7.2mg): 20.7% mean weight loss, the current benchmark for the semaglutide platform. Read the full study
-
Aronne et al. (2025) — The SURMOUNT-5 trial (tirzepatide vs semaglutide head-to-head): 20.2% vs 13.7% weight loss at standard maximum doses, establishing tirzepatide's efficacy advantage. Read the full study
-
Jastreboff et al. (2022) — The SURMOUNT-1 trial (tirzepatide 15mg for obesity): 22.5% weight loss, the benchmark for the tirzepatide weight-loss platform. Read the full study
-
Wilding et al. (2021) — The STEP 1 trial (semaglutide 2.4mg): 14.9% weight loss, the foundational study that launched the current GLP-1 weight-loss era. Read the full study